These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37283287)

  • 1. Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
    Wu W; Chen L; Jia G; Tang Q; Han B; Xia S; Jiang Q; Liu H
    Cancer Med; 2023 Jul; 12(14):15676-15690. PubMed ID: 37283287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
    Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of CD4
    Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Liu H; Chang Y; Zhu Y; Xu L; Wang Z; Wang Y; Zhang W
    Cancer Sci; 2024 Apr; 115(4):1306-1316. PubMed ID: 38402640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
    Oliushina EM; Zavalishina LE; Alekseenok EY; Oskina NA; Andreeva YY; Kuznetsova OA; Filipenko ML; Frank GA
    Arkh Patol; 2023; 85(2):5-12. PubMed ID: 37053347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
    Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
    J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
    Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
    Yang Z; Zhang R; Ge Y; Qin X; Kang X; Wang Y; Zhang X; Song C; Quan X; Wang H; Chen H; Li C
    EBioMedicine; 2018 Sep; 35():198-203. PubMed ID: 29941343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Kobatake K; Ikeda K; Kohada Y; Tasaka R; Takemoto K; Fukushima T; Miyamoto S; Sekino Y; Kitano H; Goto K; Hieda K; Goriki A; Hayashi T; Hinata N
    Anticancer Res; 2024 May; 44(5):1947-1954. PubMed ID: 38677755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of The Immune Subtype Among Muscle-invasive Bladder Cancer Patients by Multiple Datasets.
    Shinwari K; Chen Z; Liu G; Chen L; Bolkov MA; Tuzankina IA; Chereshnev VA
    Acta Med Indones; 2022 Jan; 54(1):62-71. PubMed ID: 35398827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic alteration and prognostic significance of tumor-associated CD68
    Wu J; Xie RY; Wei LH; Cao CZ; Shang BQ; Guan YY; Shi HZ; Qu W; Li Y; Liang J; Zheng S; Zhou AP; Zhou XF; Shou JZ; Bi XG
    Cancer Med; 2023 Feb; 12(4):4981-4992. PubMed ID: 36043478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.
    Le Goux C; Vacher S; Schnitzler A; Barry Delongchamps N; Zerbib M; Peyromaure M; Sibony M; Allory Y; Bieche I; Damotte D; Pignot G
    Sci Rep; 2020 Oct; 10(1):16641. PubMed ID: 33024200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
    Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.